-
甲状腺癌分为分化型和未分化型两种,其中以分化型甲状腺癌(differentiated thyroid cancer,DTC)居多,其发病率呈逐年上升的趋势。DTC起源于甲状腺滤泡上皮细胞,主要包括甲状腺乳头状癌和甲状腺滤泡状癌。大部分DTC进展缓慢,近似良性病程,10年生存率约95%,但高达25%的患者会发生局部病灶复发或远处转移,约有4%~8%的乳头状癌和15%~19%的滤泡状癌患者发生远端转移[1-2]。据文献报道,DTC远处转移最常见的部位是肺(49%),其次是骨(25%)[3],一旦DTC发生骨转移,生存率会降至20%以下[4],DTC骨转移的发生率为4%~13%[5-8]。
分化型甲状腺癌骨转移诊断及疗效评价的核素显像研究进展
Diagnosis and evaluation of curative effect progress of radionuclide imaging methods in differentiated thyroid cancer of bone metastases
-
摘要: 分化型甲状腺癌(DTC)骨转移的诊断及疗效评价的核素显像方法较多,放射性核素显像在恶性肿瘤骨转移中的临床应用比较广泛,在DTC骨转移中主要用于骨转移的诊断、术后随访及疗效评价。放射性核素显像目前主要包括SPECT显像和PET显像,前者包括131I显像、99Tcm-MDP显像等,后者包括124I显像、18F-FDG显像、18F-NaF显像等。笔者将放射性核素显像方法在DTC骨转移中的诊断及治疗进展进行综述。
-
关键词:
- 甲状腺肿瘤 /
- 体层摄影术, 发射型计算机, 单光子 /
- 正电子发射断层显像术 /
- 体层摄影术, X线计算机 /
- 骨转移
Abstract: There are various radionuclide imaging modalities for the diagnosis and evaluation of curative effect about differentiated thyroid cancer with bone metastases. Radionuclide imaging is widely used in many kinds of malignant tumors with bone metastases. Recently, SPECT and PET are main included in the radionuclide imaging.The former main contains 131I、99Tcm-MDP imaging and the later one main contains 124I、18F-FDG as wall as 18F-NaF imaging. This review concentrates on the commonly used radionuclide imaging methods in patients with DTC of bone metastases. -
[1] Davies L, Welch HG.Current thyroid cancer trends in the United States[J].JAMA Otolaryngol Head Neck Surg, 2014, 140(4):317-322. DOI:10.1001/jamaoto.2014.1. [2] Shaha AR.Recurrent differentiated thyroid cancer[J].Endocr Pract, 2012, 18(4):600-603. DOI:10.4158/EP12047.CO. [3] Orita Y, Sugitani I, Matsuura M, et al.Prognostic factors and the therapeutic strategy for patients with bone metastasis from differentiated thyroid carcinoma[J].Surgery, 2010, 147(3):424-431. DOI:10.1016/j.surg.2009.10.009. [4] Bechsgaard T, Lelkaitis G, Jensen KE, et al.Diagnosis of bone metastasis from thyroid carcinoma:a multidisciplinary approach[J].Acta Radiol Open, 2015, 4(11):1-3. DOI:10.1177/2058460115603248. [5] Pittas AG, Adler M, Fazzari M, et al.Bone metastases from thyroid carcinoma:clinical characteristics and prognostic variables in one hundred forty-six patients[J].Thyroid, 2000, 10(3):261-268. DOI:10.1089/thy.2000.10.261. [6] Lin JD, Huang MJ, Juang JH, et al.Factors related to the survival of papillary and follicular thyroid carcinoma patients with distant metastases[J].Thyroid, 1999, 9(12):1227-1235. DOI:10.1089/thy.1999.9.1227. [7] Kallel F, Hamza F, Charfeddine S, et al.Clinical features of bone metastasis for differentiated thyroid carcinoma:A study of 21 patients from a Tunisian center[J].Indian J Endocrinol Metab, 2014, 18(2):185-190. DOI:10.4103/2230-8210.129109. [8] 邱忠领.131I治疗分化型甲状腺癌骨转移的临床研究[D].苏州: 苏州大学, 2010.
Qiu ZL.Clinical Study of 131I for the Treatment of bone metastases from differentiated thyroid cancer[D].Suzhou: Soochow University, 2010.[9] 杨辉, 田辉英, 李文亮, 等.核素全身骨显像在多发性骨髓瘤诊断中的应用价值[J].肿瘤影像学, 2013, 22(3):223-226.
Yang H, Tian HY, Li WL, et al.Application value of whole-body scan in diagnosis of multiple myeloma[J].Oncoradiology, 2013, 22(3):223-226.[10] Pacini F, Capezzone M, Elisei R, et al.Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment[J].J Clin Endocrinol Metab, 2002, 87(4):1499-1501. DOI:10.1210/jcem.87.4.8274. [11] Torlontano M, Crocetti U, D'aloiso L, et al.Serum thyroglobulin and 131I whole body scan after recombinant human TSH stimulation in the follow-up of low-risk patients with differentiated thyroid cancer[J].Eur J Endocrinol, 2003, 148(1):19-24. DOI:10.1530/eje.0.1480019. [12] Carril JM, Quirce R, Serrano J, et al.Total-body scintigraphy with thallium-201 and iodine-131 in the follow-up of differentiated thyroid cancer[J].J Nucl Med, 1997, 38(5):686-692. [13] Muratet JP, Giraud P, Daver A, et al.Predicting the efficacy of first iodine-131 treatment in differentiated thyroid carcinoma[J].J Nucl Med, 1997, 38(9):1362-1368. [14] Fatourechi V, Hay ID, Mullan BP, et al.Are posttherapy radioiodine scans informative and do they influence subsequent therapy of patients with differentiated thyroid cancer[J].Thyroid, 2000, 10(7):573-577. DOI:10.1089/thy.2000.10.573. [15] Souza Rosário PW, Barroso AL, Rezende LL, et al.Post I-131 therapy scanning in patients with thyroid carcinoma metastases:an unnecessary cost or a relevant contribution[J].Clin Nucl Med, 2004, 29(12):795-798. doi: 10.1097/00003072-200412000-00005 [16] 陶衍能, 陈汉华, 韦令欣.131I治疗分化型甲状腺癌骨转移的疗效评价[J].中华全科医学, 2012, 10(12):1896-1897. DOI:10.16766/j.cnki.issn.1674-4152.2012.12.093.
Tao YN, Chen HH, Wei LX.The evaluation of curative in differentiated thyroid cancer of bone metastases with the treatment of 131I[J].Chin J Gen Pract, 2012, 1012(12):1896-1897. doi: 10.16766/j.cnki.issn.1674-4152.2012.12.093[17] 程旭, 李永军, 徐兆强, 等.治疗剂量131I SPECT/CT显像评价分化型甲状腺癌骨转移[J].标记免疫分析与临床, 2015, 22(11):1095-1098. DOI:10.11748/bjmy.issn.1006-1703.2015.11.007.
Cheng X, Li YJ, Xu ZQ, et al.Application of 131I SPECT/CT fusion imaging for evaluation bone metastasis in patients witn DTC[J].Labeled Immunoassays Clin Med[J].2015, 22(11):1095-1098. doi: 10.11748/bjmy.issn.1006-1703.2015.11.007[18] 白青山, 秦莎娜, 张海龙, 等.SPECT/CT同机融合显像对骨转移瘤的诊断价值[J].内蒙古医学杂志, 2014, 46(1):88-89.
Bai QS, Qin SN, Zhang HL, et.al.Value of SPECT/CT fusion imaging in the diagnosis of bone metastases[J].Inner Mongolia Med J, 2014, 46(1):88-89.[19] Qiu ZL, Xue YL, Song HJ, et al.Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer[J].Nucl Med Commun, 2012, 33(12):1232-1242. DOI:10.1097/MNM.0b013e328358d9c0. [20] Kotb MH, Omar W, El-Maghraby T, et al.The value of simultaneous co-registration of 99mTc-MDP and 131Iodine in metastatic differentiated thyroid carcinoma[J].Nucl Med Rev Cent East Eur, 2007, 10(2):98-105. [21] 段东升, 任媛.分化型甲状腺癌骨转移临床分析[J].中国药物与临床, 2014, 14(5):662-663. DOI:10.11655/zgywylc2014.05.048.
Duan DS, Ren Y, The clinical analysis of differentiated thyroid cancer of bone metastases[J].Chi Remed Clin, 2014, 14(5):662-663. doi: 10.11655/zgywylc2014.05.048[22] Agate L, Bianchi F, Giorgetti A, et al.Detection of metastases from differentiated thyroid cancer by different imaging techniques(neck ultrasound, computed tomography and [18F]-FDG positron emission tomogr-aphy)in patients with negative post-therapeutic 131I whole-body scan and detectable serum thyroglobulin levels[J].J Endocrinol Invest, 2014, 37(10):967-972. DOI:10.1007/s40618-014-0134-1. [23] 齐红艳, 孙逊, 安锐.骨转移瘤影像学检查方法及相关进展[J].华中科技大学学报(医学版), 2015, 44(1):121-124. DOI:10.3870/j.issn.1672-0741.2015.01.025.
Qi HY, Sun X, An R.The imaging methods and progress of bone metastatic tumors[J].Acta Med Univ Sci Technol Huazhong, 2015, 44(1):121-124. doi: 10.3870/j.issn.1672-0741.2015.01.025[24] Kotb MH, Omar W, El-Maghraby T, et al.The value of simultaneous co-registration of 99mTc-MDP and 131Iodine in metastatic differentiated thyroid carcinoma[J].Nucl Med Rev Cent East Eur, 2007, 10(2):98-105. [25] 谭涛.SPECT-PET显像在分化型甲状腺癌131I治疗预后中的应用价值[J].河南外科学杂志, 2012, 18(4):12-15. doi: 10.3969/j.issn.1007-8991.2012.04.008
Tan T.Applications of SPECT-PET in the splitting up type cancer 131I therapy prognosis of differentiated thyroid carcinoma[J].Henan J Surg, 2012, (4):12-15. doi: 10.3969/j.issn.1007-8991.2012.04.008[26] 王姝, 李亚明, 李娜, 等.溶骨性骨代谢增高病灶的SPECT/CT骨显像特点及与CT表现的相关性[J].中华核医学与分子影像杂志, 2015, 35(6):466-469. DOI:10.3760/cma.j.issn.2095-2848.2015.06.011.
Wang S, Li YM, Li N, et al.SPECT/CT imaging characteristic of osteolytic lesions with increased bone metabolism and its correlation with CT manifestation[J].Chin J Nuclear Med Mol Imaging, 2015, 35(6):466-469. doi: 10.3760/cma.j.issn.2095-2848.2015.06.011[27] Lopci E, Chiti A, Castellani MR, et al.Matched pairs dosimetry:124I/131I metaiodobenzylguanidine and 124I/131I and 86Y/90Y antibodies[J].Eur J Nucl Med Mol Imaging, 2011, 38 Suppl 1:S28-S40. DOI:10.1007/s00259-011-1772-6. [28] Rault E, Vandenberghe S, Van Holen R, et al.Comparison of image quality of different Iodine isotopes(I-123, I-124, and I-131)[J].Cancer Biother Radiopharm, 2007, 22(3):423-30. DOI:10.1089/cbr.2006.323. [29] Phan HT, Jager PL, Paans AM, et al.The diagnostic value of 124I-PET in patients with differentiated thyroid cancer[J].Eur J Nucl Med Mol Imaging, 2008, 35(5):958-965. DOI:10.1007/s00259-007-0660-6. [30] Van Nostrand D, Moreau S, Bandaru VV, et al.124I positron emission tomography versus 131I planar imaging in the identification of residual thyroid tissue and/or metastasis in patients who have well-differentiated thyroid cancer[J].Thyroid, 2010, 20(8):879-883. DOI:10.1089/thy.2009.0430. [31] 刘斌, 郭佳, 王建涛, 等.124I PET/CT在分化型甲状腺癌诊治中的应用[J].中华核医学与分子影像杂志, 2013, 33(1):71-74 DOI:10.3760/cma.j.issn.2095-2848.2013.01.021.
Liu B, Guo J, Wang JT, et al.Clinical applications of 124I PET/CT in patients with differentiated thyroid carcinoma[J].Chin J Nucl Med Mol Imaging, 2013, 33(1):71-74. doi: 10.3760/cma.j.issn.2095-2848.2013.01.021[32] Capoccetti F, Criscuoli B, Rossi G, et al.The effectiveness of 124I PET/CT in patients with differentiated thyroid cancer[J].Q J Nucl Med Mol Imaging, 2009, 53(5):536-545. [33] 黄蕤, 匡安仁.18F-FDG正电子断层显像在分化型甲状腺癌中的应用进展[J].生物医学工程学杂志, 2014, 31(2):445-451.
Huang R, Kuang AR.Application progress of 18F-FDG positron emission tomograph in differentiated thyroid cancer[J].J Biomed Eng, 2014, 31(2):445-451.[34] Nahas Z, Goldenberg D, Fakhry C, et al.The role of positron emission tomography/computed tomography in the management of recurrent papillary thyroid carcinoma[J].Laryngoscope, 2005, 115(2):237-243. DOI:10.1097/01.mlg.0000154725.00787.00. [35] 范群, 匡安仁, 袁耿彪.18F-FDG PET显像在分化型甲状腺癌患者随访中的应用[J].现代生物医学进展, 2006, 6(9):42-46. DOI:10.3969/j.issn.1673-6273.2006.09.015.
FanQ, Kuang AR, Yuan GB.18F-FDG PET application in the differentiated thyroid cancer[J].Prog Mod Biomed, 2006, 6(9):42-46. doi: 10.3969/j.issn.1673-6273.2006.09.015[36] Shon IH, Depcynzski B, Lin M, et al.Positron emission tomography in non-medullary thyroid cancer[J].ANZ J Surg, 2011, 81(3):116-124. DOI:10.1111/j.1445-2197.2010.05538.x. [37] Treglia G, Muoio B, Giovanella L, et al.The role of positron emission tomography and positron emission tomography/computed tomography in thyroid tumours:an overview[J].Eur Arch Otorhinolaryngology, 2013, 270(6):1783-1787. DOI:10.1007/s00405-012-2205-2. [38] Riemann B, Uhrhan K, Dietlein M, et al.Diagnostic value and therapeutic impact of 18F-FDG-PET/CT in differentiated thyroid cancer.Results of a German multicentre study[J].Nuklearmedizin, 2013, 52(1):1-6. DOI:10.3413/nukmed-0489-12-03. [39] Seo YL, Yoon DY, Baek S, et al.Detection of neck recurrence in patients with differentiated thyroid cancer:comparison of ultrasound, contrast-enhanced CT and 18F-FDG PET/CT using surgical pathology as a reference standard:(ultrasound vs.CT vs.(18)F-FDG PET/CT in recurrent thyroid cancer)[J].Eur Radiol, 2012, 22(10):2246-2254. DOI:10.1007/s00330-012-2470-x. [40] Choi WH, Chung YA, Han EJ, et al.Clinical value of integrated[18F]fluoro-2-Deoxy-D-Glucose positron emission tomography/computed tomography in the preoperative assessment of papillary thyroid carcinoma[J].J Ultrasound Med, 2011, 30(9):1267-1273. doi: 10.7863/jum.2011.30.9.1267 [41] Kim BS, Kim SJ, Kim IJ, et al.Factors associated with positive F-18 flurodeoxyglucose positron emission tomography before thyroidectomy in patients with papillary thyroid carcinoma[J].Thyroid, 2012, 22(7):725-729. DOI:10.1089/thy.2011.0031. [42] 武凤玉, 王振光.18F-FDG PET/CT显像在甲状腺肿瘤中的应用[J].中华核医学与分子影像杂志, 2016, 36(2):192-195. DOI:10.3760/cma.j.issn.2095-2848.2016.02.023.
Wu FY, Wang ZG.The application of 18F-FDG PET/CT in thyroid tumor[J].Chin J Nucl Med Mol Imaging, 2016, 36(2):192-195. doi: 10.3760/cma.j.issn.2095-2848.2016.02.023[43] 吕中伟, 朱承谟, 管梁, 等.18F-FDG PET显像与99Tcm-MDP全身骨显像诊断肿瘤远处转移的比较[J].中华核医学杂志, 2001, 21(4):209-210. doi: 10.3760/cma.j.issn.2095-2848.2001.04.007
Lyu ZW, Zhu CM, Guan L, et al.Comparative study of 18F-FDG PET imaging and 99Tcm-MDP whole body bone imaging in detection of remote metastasis[J].Chin J Nucl Med, 2001, 21(4):209-210. doi: 10.3760/cma.j.issn.2095-2848.2001.04.007[44] 祝安惠, 王荣福.PET/CT与全身骨显像诊断不同类型骨转移瘤的对比[J].中国医学影像技术, 2016, 32(6):944-948. DOI:10.13929/j.1003-3289.2016.06.034.
Zhu AH, Wang RF.Comparison of diagnostic capability on different types of bone metastases between PET/CT and whole-body bone scan[J].Chin J Med Imaging Technol, 2016, 32(6):944-948. doi: 10.13929/j.1003-3289.2016.06.034[45] Raijmakers P, Temmerman OP, Saridin CP, et al.Quantification of 18F-Fluoride kinetics:evaluation of simplified methods[J].J Nucl Med, 2014, 55(7):1122-1127.D:10.2967/jnumed.113.135269. [46] Wondergem M, Van Der Zant FM, Van Der Ploeg T, et al.A literature review of F-18-fluoride PET/CT and F-18-choline or C-11-choline PET/CT for detection of bone metastases in patients with prostate cancer[J].Nucl Med Commun, 2013, 34(10):935-945. DOI:10.1097/MNM.0b013e328364918a. [47] Frost ML, Compston JE, Goldsmith D, et al.18F-fluoride positron emission tomography measurements of regional bone formation in hemodialysis patients with suspected adynamic bone disease[J].Calcif Tissue Int, 2013, 93(5):436-447. DOI:10.1007/s00223-013-9778-7. [48] Schirrmeister H, Glatting G, Hetzel J, et al.Prospective evaluation of the clinical value of planar bone scans, SPECT, and F-18-labeled NaFPET in newly diagnosed lung cancer[J].J Nucl Med, 2001, 42(12):1800-1804. [49] 张胤, 陈跃.18F-氟化钠PET/CT诊断肿瘤骨转移应用进展[J].国际放射医学核医学杂志, 2015(1):96-102. DOI:10.3760/cma.j.issn.1673-4114.2015.01.020.
Zhang Y, Chen Y.Application progress of 18F-NaF PET/CT in the diagnosis of neoplasm metastases[J].Int J Radiat Med Nucl Med, 2015(1):96-102. doi: 10.3760/cma.j.issn.1673-4114.2015.01.020[50] Caldarella C, Treglia G, Giordano A, et al.When to perform positron emission tomography/computed tom ography or radionuclide bone scan in patients with recently diagnosed prostate cancer[J].Cancer Manag Res, 2013, 5:123-131. DOI:10.2147/CMAR.S34685. [51] Tateishi U, Morita S, Taguri M, et al.A meta-analysis of 18F-Fluoride positron emission tomography for assessment of metastatic bone tumor[J].Ann Nucl Med, 2010, 24(7):523-531. DOI:10.1007/s12149-010-0393-7. [52] 黄禾, 陈跃.18F-NaF PET/CT在骨良性病变中的临床应用与研究进展[J].中国医学影像技术, 2016, 32(3):457-460. DOI:10.13929/j.1003-3289.2016.03.035.
Huang H, Chen Y.Clinical application and progresses of 18F-NaF PET/CT in benign lesions of the bones[J].Chin J Med Imaging Technol, 2016, 32(3):457-460. doi: 10.13929/j.1003-3289.2016.03.035[53] Chan SC, Wang HM, Ng SH, et al.Utility of 18F-fluoride PET/CT and 18F-FDG PET/CT in the detection of bony metastases in heightened-risk head and neck cancer patients[J].J Nucl Med, 2012, 53(11):1730-1735. DOI:10.2967/jnumed.112.104893. [54] Ota N, Kato K, Iwano S, et al.Comparison of 18F-fluoride PET/CT, 18F-FDG PET/CT and bone scintigraphy (planar and SPECT)in detection of bone metastases of differentiated thyroid cancer:a pilot study[J].Br J Radiol, 2014, 87(1034):20130444. DOI:10.1259/bjr.20130444. [55] Harisankar CN, Agrawal K, Bhattacharya A, et al.F-18 fluoro-deoxy-glucose and F-18 Sodium fluoride cocktail PET/CT scan in patients with breast cancer having equivocal bone SPECT/CT[J].Indian J Nucl Med, 2014, 29(2):81-86. DOI:10.4103/0972-3919.130287. [56] 吉蘅山, 孙传金, 朱虹, 等.18F-NaF PET/CT与99Tcm-MDP骨显像诊断骨转移瘤价值的对比研究[J].东南国防医药, 2015, 17(6):642-644. DOI:10.3969/j.issn.1672-271X.2015.06.025.
Ji HS, Sun CJ, Zhu H.The value of 18F-NaF PET/CT and 99mTc-MDP 18F-NaF bone imaging in the diagnosis of bone metastases[J].Military Med J Southeast China, 2015, 17(6):642-644. doi: 10.3969/j.issn.1672-271X.2015.06.025[57] Petersen H, Ogren M, Høilund-Carlsen PF.Fluoride-positron emission tomography/computed tomography for differential diagnosis in suspected bone metastasis[J].Ugeskr Laeger, 2010, 172(20):1538-1539. [58] Aparici CM, Win AZ.Use of NaF-18-Positron emission tomography/computed tomography in the detection of bone metastasis from papillary renal cell carcinoma[J].World J Nucl Med, 2014, 13(2):135-137. DOI:10.4103/1450-1147.139146. [59] Fischer DR.Musculoskeletal imaging using fluoride PET[J].Semin Nucl Med, 2013, 43(6):427-433. DOI:10.1053/j.semnuclmed.2013.06.004.
计量
- 文章访问数: 4044
- HTML全文浏览量: 3178
- PDF下载量: 6